8.670USD+0.81%Mkt Cap: 455.33M USDP/E: —Last update: 2026-05-26
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap455.33M USD
Enterprise Value83.92M USD
Revenue (TTM)88.24M USD
Gross Profit-128.53M USD
Net Income (TTM)-140.11M USD
Revenue/Share1.446 USD
Last Price8.670 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees196
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.33
PEG—
EV/EBITDA-0.49
EV/Revenue0.95
P/S5.15
P/B1.01
EPS (TTM)-2.57
EPS (Forward)-3.72
52W Range
3.36559% of range12.34
52W High12.34 USD
52W Low3.365 USD
Profitability
Gross Margin-145.66%
Oper. Margin-2416.15%
EBITDA Margin-194.28%
Profit Margin-164.43%
ROE-27.71%
ROA-24.72%
Growth
Revenue Growth21664.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-109.08M USD
CapEx (TTM)536.00K USD
FCF Margin-78.60%
FCF Yield-15.23%
Net Debt-370.36M USD
Net Debt/EBITDA2.16
Balance Sheet
Debt/Equity0.04
Current Ratio9.34
Quick Ratio9.01
Book Value/Sh8.644 USD
Cash/Share7.477 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)28.22 USD
Target Range17.00 USD – 36.00 USD
# Analysts9
Ownership
Shares Out.52.28M
Float38.84M
Insiders3.55%
Institutions98.25%
Short Interest
Short Ratio16.8d
Short % Float26.52%
Short % Out.22.94%
Shares Short11.99M
Short (prev mo.)10.86M
Technical
SMA 509.468 (-8.4%)
SMA 2008.984 (-3.5%)
Beta2.76
S&P 52W Chg28.31%
Avg Vol (30d)664.52K
Avg Vol (10d)666.58K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—